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Abstract
Cryptococcal induced visual loss is a devastating complication in survivors of cryptococcal meningitis (CM). Early detection
is paramount in prevention and treatment. Subclinical optic nerve dysfunction in CM has not hitherto been investigated by
electrophysiological means. We undertook a prospective study on 90 HIV sero-positive patients with culture confirmed CM.
Seventy-four patients underwent visual evoked potential (VEP) testing and 47 patients underwent Humphrey’s visual field
(HVF) testing. Decreased best corrected visual acuity (BCVA) was detected in 46.5% of patients. VEP was abnormal in 51/74
(68.9%) right eyes and 50/74 (67.6%) left eyes. VEP P100 latency was the main abnormality with mean latency values of
118.9 (616.5) ms and 119.8 (615.7) ms for the right and left eyes respectively, mildly prolonged when compared to our
laboratory references of 104 (610) ms (p,0.001). Subclinical VEP abnormality was detected in 56.5% of normal eyes and
constituted mostly latency abnormality. VEP amplitude was also significantly reduced in this cohort but minimally so in the
visually unimpaired. HVF was abnormal in 36/47 (76.6%) right eyes and 32/45 (71.1%) left eyes. The predominant field defect
was peripheral constriction with an enlarged blind spot suggesting the greater impact by raised intracranial pressure over
that of optic neuritis. Whether this was due to papilloedema or a compartment syndrome is open to further investigation.
Subclinical HVF abnormalities were minimal and therefore a poor screening test for early optic nerve dysfunction. However,
early optic nerve dysfunction can be detected by testing of VEP P100 latency, which may precede the onset of visual loss in
CM.
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Introduction
Cryptococcal meningitis (CM) and other opportunistic infections
in HIV infected patients continue to be a burden in developing
countries despite established antiretroviral drug treatment pro-
grammes [1]. A major challenge facing satisfactory management of
CM is the late presentation of patients with advanced AIDS at initial
presentation. Fifty percent of patients with CM present with
neurological complications, of which visual loss is the most disabling
in patients that recover [2]. Visual loss is severe, occurs early in
infection and is recorded in up to 40% of patients [3–6].
Visual loss in CM is well documented, however the pathogenesis
remains controversial. Rex et al. have suggested a dual mechanism
of early optic neuritis and late papilloedema resulting from optic
nerve infiltration and raised intracranial pressure respectively [7].
Nevertheless, conflicting reports of the optic neuritis, papilloedema
and the more recent compartment syndrome models abound in
the literature [8–11]. A definitive model is still lacking but the
compartment syndrome occurring along the nerve or at the optic
canal level seems most plausible [12,13]. A better understanding of
the pathogenesis of cryptococcal induced visual loss will certainly
provide better guidance to management and prevention of
blindness in this group. The recommended intervention to prevent
visual loss is lowering of CSF pressure, either by serial lumbar
punctures, in situ lumbar drain or optic nerve sheath fenestration
[8,14–16]. However the likelihood of optic nerve infiltration and
the benefit of corticosteroids have not been entirely excluded as
treatment option as demonstrated pathologically by Corti et al
that fungal infiltration of the optic nerve does occur and by De
Schacht et al of the benefit of corticosteroids especially in the
setting of immune reconstitution [17,18].
The Visual Evoked Potential (VEP) is reproducible and the
P100 waveform is easily identified and analysed. Full field
monocular pattern-reversal VEP is a useful test of pre-chiasmic
optic nerve function. VEP findings of prolonged latency and
reduced amplitude suggest optic nerve dysfunction, which in the
setting of early visual loss in CM points to optic nerve infiltration.
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Chronic papilloedema may also have similar VEP changes but will
not be expected to occur early in the disease. Furthermore, central
and centrocecal scotomata early in CM point to optic nerve
dysfunction whereas a large blind spot and constricted field will
suggest papilloedema related dysfunction. Automated Humphrey’s
Visual Field (HVF) is not operator dependent and qualitatively
offers useful localization of visual pathway dysfunction. Its
limitation however is in patients with severe visual loss who
cannot be tested. The electrophysiology of optic nerve dysfunction
in CM is poorly documented and whether it can contribute
towards the discussion of pathogenesis and subclinical disease has
not hitherto been explored. Mwanza et al. have demonstrated
VEP abnormalities in 57% and 42% of HIV infected patients with
and without neurological symptoms, although it is unclear what
the burden of CM disease was in these patients [19].
The primary aim of this study was to establish the extent of the
electrophysiological disturbance within the optic nerve in patients
with CM by examining VEP and comparing with automated
HVF. The detection of subclinical disease within the optic nerve
by electrophysiological means could potentially identify patients
most at risk of developing visual loss. Further correlation with the
patients’ immune status, visual acuity, optic disc appearance and
CSF pressure was made. The secondary aim was to determine if
VEP and HVF could contribute to the optic neuritis vs.
papilloedema vs. compartment syndrome debate with regard to
the pathogenesis of cryptococcal induced visual loss.
Materials and Methods
Ethical approval was obtained from the University of KwaZulu-
Natal and Greys Hospital ethics committees. Informed consent
was obtained from 90 patients with CM, confirmed on fungal
culture, who were consecutively recruited from February 2008 to
January 2011. Patients underwent visual evoked potential testing,
visual field testing, neuro-ophthalmological assessment and lumbar
punctures, which formed part of their routine work-up for chronic
meningitis. Recruitment of patients occurred within 2 weeks of
commencement of treatment and usually within 4 weeks of
symptom onset of meningitis. CNS co-infection with tuberculosis,
toxoplasmosis, syphilis or any other opportunistic infection, when
identified, was an exclusion criterion. Lack of co-operation by
encephalopathic patients precluded VEP and HVF testing. Flash
light emitting diode (LED) goggles VEP was done for 6 patients
who could not fixate due to severe visual loss or inattention.
VEP recordings were obtained monocularly. Full field pattern-
reversal VEPs were elicited by checkerboard stimuli of large 1
degree (i.e. 60 min of arc) checks and detected using silver
electrodes placed over the scalp in accordance with ISCEV
guidelines [20]. The P100 latency and peak to peak N80 – P100
amplitude were considered for analysis.
Automated Humphreys Visual Fields were performed using the
30–2 SITA standard protocol. Only pattern deviation fields that
fulfilled acceptable reliability indices were included for analysis.
Acceptable reliability indices of HVF were fixation losses ,33%,
false negatives ,33% and false positives ,33%.
Stastistics
Visual acuity, VEP latency and amplitude were dichotomized
into abnormal and normal groups using standard normal
references. A best corrected visual acuity of ,6/6 on the Snellen
chart, VEP P100 latency of .114 ms and VEP N80-P100
amplitude of ,10 mV were considered abnormal. A CSF opening
pressure of #20 cmH2O was considered normal. One sample t
tests were used to compare mean latency and amplitude to
laboratory references. Tests for association between groups were
analysed using a Chi Square test or Fisher’s exact test as
appropriate. Statistical analysis was done in STATA, version 12.
Results
All 90 patients recruited were HIV sero-positive and co-infected
with Cryptococcus neoformans. All were black African, 50 (55.6%) were
males and the mean age of the entire group was 33.5 yrs (range 17–
51).
Of the 90 patients recruited, 86 patients had visual acuity testing
but 4 were too encephalopathic for testing. Seventy-four patients
underwent VEP testing and 47 patients underwent HVF testing.
Ten right eyes and 8 left eyes had absent VEP responses therefore 64
right eyes and 66 left eyes were subjected to quantitative VEP
analysis for discrete latency and amplitude evaluation. HVF was
done on 47 right eyes and 45 left eyes. Thedisparitywas due to an old
enucleation of one eye and post traumatic blindness in the other eye
(Table 1). Sixteen patients had profound visual loss of ,6/60 on
whom HVF could not be performed. The results of flash LED-
goggles VEP on 6 patients, who were unco-operative, were not
reproducible, too unreliable and not included for analysis. Only full
field pattern reversal VEPs were included for analysis.
While 40/86 (46.5%) patients had decreased best corrected
visual acuity (BCVA), profound visual loss of ,6/60 was detected
in 16/40 (40%) of those patients (19% in total). VEP was
abnormal in 51/74 (68.9%) right eyes and 50/74 (67.6%) left eyes
(Table 1). Of the 85 eyes with normal visual acuity, 48 (56.5%) had
an abnormal VEP parameter (latency and/or amplitude). The
mean VEP P100 latency was prolonged and N80-P100 amplitude
reduced in both eyes when compared to our laboratory references.
The mean VEP P100 latencies for the right and left eyes were
118.9 (616.5) ms and 119.8 (615.7) ms respectively, and for the
N80-P100 amplitude were 7.4 (63.9) mV and 7.0 (63.7) mV
respectively. Our laboratory references for these parameters are
104 (610) ms for VEP P100 latency and 15 (65) mV for the N80 –
P100 amplitude. Mean latency and amplitude differed significantly
from hospital references, p,0.001. A further breakdown of these
abnormalities show that the P100 latency alone was abnormal in
55/130 (42.3%) eyes, the N80-P100 amplitude alone was reduced
in 19/130 (14.6%) eyes and together was abnormal in 9/130
(6.9%) eyes (Table 2).
HVF was abnormal in 36/47 (76.6%) right eyes and 32/45
(71.1%) left eyes (Table 1). Peripheral constriction of the visual field
and a large blind spot were the predominant defects, followed by
central and paracentral scotomata, suggesting the greater impact by
raised intracranial pressure over optic nerve infiltration (Figure 1).
Table 1. Frequencies of Abnormal VA, VEP and HVF.
Visual
acuity VEP VEP HVF HVF
,6/6
Right
Eye
Left
Eye
Right
Eye
Left
Eye
N (%) N (%) N (%) N (%) N (%)
Total
Number
86 (100) 74 (100) 74 (100) 47 (100) 45 (100)
Normal 46 (53.5) 23 (31.1) 24 (32.4) 11 (23.4) 13 (28.9)
Abnormal 40 (46.5) 51 (68.9) 50 (67.6) 36 (76.6) 32 (71.1)
N – Number, VEP – Visual Evoked Potential, HVF – Humphrey’s Visual Field.
doi:10.1371/journal.pone.0052895.t001
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Significant correlations were noted between Visual Acuity and
VEP latency of the right eye (p = 0.003) and VEP latency of the left
eye (p = 0.03,) but not with VEP amplitude (Table 3). When
BCVA was abnormal 17/24 (70.8%) and 15/21 (71.4%) of VEP
latency was abnormal in the right and left eyes respectively. When
BCVA was normal, 13/40 (32.5%) and 19/45 (42.2%) of
subclinical VEP latency abnormality was detected. VEP amplitude
however did not have a similar relationship, being normal in 19/
24 (79.2%) and 18/21 (85.7%) of right and left eyes respectively,
when BCVA was abnormal. Subclinical detection of VEP
amplitude abnormality was detected in 10/40 (25%) and 10/45
(22.2%) of the right and left eyes respectively.
Swollen optic disc was correlated with VEP P100 latency for the
right and left eyes (p = 0.02, 0.047 resp.) but not with VEP
amplitude. No significant correlations were noted between CSF
pressure and CD4 count with VEP latency and amplitude (Table 3).
Table 4 demonstrates significant correlation between VEP
latency and HVF in both eyes (p = 0.001, 0.0049). BCVA is
correlated with HVF of the right eye, but not the left (p = 0.03 vs
p = 0.5). Whilst this may reflect the impact of central scotomata on
visual acuity testing, figure 1 shows equal frequency of central
scotomata in the right and left eyes. Therefore subclinical and
asymmetrical optic nerve dysfunction is a possible explanation.
When BCVA was abnormal, 17/36 (47.2%) and 10/32 (31.2%) of
the right and left HVF were abnormal. Subclinical HVF
abnormality was only detected in 1/11 (9.1%) and 2/13 (15.4%)
of right and left eyes respectively.
Discussion
Cryptococcal induced visual loss can be devastating and, if
neglected, irreversible [21]. Despite the easy availability of
antiretroviral therapy in some developing countries, the neuro-
opthalmological complications of HIV infection and cryptococcal
meningitis are still encountered. Studies have shown that early and
intensive management of raised intracranial pressure in CM can
reverse the visual loss associated with the disease [8,9]. Unfortu-
nately, due to the encephalopathic state of most patients with CM
and the lack of vigilance by medical personnel in emergency
departments visual acuity is not tested or crude testing is done on
admission. Early detection of visual impairment is therefore missed
and the window of opportunity to reverse optic nerve damage is
often lost.
The first aim of this study was to detect the frequency of VEP
and HVF abnormalities in patients with CM, correlate these
findings with visual acuity, thereby determining the presence of
clinical and subclinical disease. The second aim was to determine
if this unique VEP and HVF data could contribute to the optic
Table 2. VEP latency and amplitude findings in 66 patients.
VEP Latency and
Amplitude VA Right Eye
Total for
Right Eye VA Left Eye
Total for
Left eye
VA
Combined (%)
Total for
both eyes
Normal Abnormal n =64 Normal Abnormal n =66
Normal
n=85
Abnormal
n=45 n=130 (100)
Norm lat/Norm amp 18 5 23 19 5 24 37 (78.7) 10 (21.3) 47 (36.2)
Norm lat/Abn amp 9 2 11 7 1 8 16 (84.2) 3 (15.8) 19 (14.6)
Abn lat/Norm amp 12 14 26 16 13 29 28 (50.9) 27 (49.1) 55 (42.3)
Abn lat/Abn amp 1 3 4 3 2 5 4 (44.4) 5 (55.6) 9 (6.9)
Total Abn Latency 13 17 30 19 15 34 32 (50) 32 (50) 64
Total Abn Amplitude 10 5 15 10 3 13 20 (71.4) 8 (28.6) 28
VEP – Visual Evoked Potential, VA – Visual Acuity, Norm – normal, lat – latency, amp – amplitude, Abn – abnormal.
doi:10.1371/journal.pone.0052895.t002
Figure 1. Frequencies of Visual Field Defects. Constricted VF – Constricted Visual Field.
doi:10.1371/journal.pone.0052895.g001
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neuritis vs. papilloedema vs. compartment syndrome debate
surrounding the pathogenesis of cryptococcal induced visual loss.
Visual impairment was detected in 40/86 (46.5%) of patients
with CM, and 16/40 (40%) had profound visual loss of ,6/60
(19% in total). VEP abnormalities were detected more frequently,
occurring in 68.9% of right eyes and 67.6% of left eyes and
subclinical disease in 56.5% (Tables 1 and 2). The predominant
abnormal VEP parameter was prolongation of the P100 latency
occurring in 42.3% of all eyes (table 2). The mean P100 latency
values were 118.9 (616.5) ms and 119.8 (615.7) ms for the right
and left eyes respectively, mildly prolonged when compared to our
laboratory references of 104 (610) ms but still significant
(p,0.001). Prolonged P100 latencies suggest demyelination or
conduction block (focal demyelination), as occurs in acute optic
neuritis which in the case of CM, a non-demyelinating disorder,
will suggest focal pressure effects on the optic nerve. Conceivably
the most likely sites of optic nerve compression will be at the optic
canal or at sites of dense subarachnoid trabeculae within the optic
nerve sheath, providing soft evidence for the compartment
syndrome in cryptococcal induced visual loss.
VEP latency strongly correlated with visual acuity and swollen
optic disc; when VEP latency was prolonged, visual acuity was
reduced and optic disc swelling occurred (Table 3). Such abnormal
parameters provide strong clinical and electrophysiological
evidence for optic nerve dysfunction in cryptococcal induced
visual loss. The fact that 32.5% and 42.2% of right and left eyes
respectively with normal acuity had prolonged VEP latency is
good evidence for subclinical optic nerve dysfunction. The
contribution to prolonged VEP latency made by the HIV virus
in advanced HIV infection requires further evaluation. Claims of
subclinical VEP abnormalities in 3–49% of HIV infected patients
due to retro-chiasmic or occipital cortical neuron loss have not
been verified [19,22]. Mwanza’s group did not exclude crypto-
coccal meningitis and it is likely that the 49% includes patients
with cryptococcal meningitis. In Malessa’s group of asymptomatic
HIV-infected patients, 3% had VEP latency prolongation and
33% had VEP amplitude reduction when CD4 counts were below
100. However in the setting of co-infection with CM, and noting
the prominence played by the fungus in visual loss, one has to
presume that a large amount of the 56.5% of overall VEP
abnormality (latency and amplitude) in our patients was due to
cryptococcal co-infection rather than HIV alone (Table 2). A
limitation of this study is the failure of comparison to an
asymptomatic HIV positive group without CM to determine the
impact if any of HIV infection itself. No significant correlations
were noted between VEP latency and CSF pressure or CD4
counts (Table 3), possibly due to the relatively small number of
patients recruited or that VEP and CSF pressure measurements
were not always done at the same time.
VEP amplitude changes occurred less frequently and this was
the abnormality in only 14.6% of eyes suggesting that secondary
axonal changes were not frequent despite the low mean amplitude
of 7.4 (63.9) mV and 7.0 (63.7) mV for the right and left eyes
respectively.(Table 2). The low frequency of amplitude changes
may be a reflection of the somewhat early recruitment of patients
from symptom onset (4 weeks). Perhaps repeat testing later in the
disease may reveal more secondary axonal change, which is a late
phenomenon. Consequently, no significant correlations were
noted between VEP amplitude and visual acuity, CSF pressure,
optic disc swelling or CD4 counts in early CM. (Table 2).
HVF abnormalities were very frequent in patients who could be
tested, occurring in 76.6% of right eyes and 71.1% of left eyes.
(Table 1) A major limitation of HVF testing was that patients with
profound visual loss (VA ,6/60) could not be tested. The
predominant field defects were peripheral constriction with large
blind spots followed by central and paracentral field defects.
Table 4. Correlation between HVF and VA, CSF Pressure, Swollen optic disc, CD4 count and VEP in 47 patients.
HVF of Right Eye p value HVF of Left Eye P value
n=47 n=45
Normal Abnormal Normal Abnormal
Visual Acuity Normal 10 1 0.03 11 2 0.5
(90.9%) (9.1%) (84.6%) (15.4%)
Abnormal 19 17 22 10
(52.8%) (47.2%) (68.8%) (31.2%)
CSF Pressure Normal 2 9 0.9 4 8 0.4
Elevated 8 25 6 24
Swollen optic disc No 7 4 0.9 9 4 0.8
Yes 22 13 20 11
CD4 count ,50 4 19 0.7 4 18 0.14
50–100 3 9 5 6
101–199 0 2 0 2
.200 1 0 1 0
VEP latency Normal 10 10 0.001 9 10 0.0049
Abnormal 1 20 4 19
VEP amplitude Normal 5 6 0.1 3 6 0.1
Abnormal 6 24 10 23
HVF – Humphrey’s visual field, VEP – Visual evoked potential, Visual Acuity refers to Best Corrected Visual Acuity.
doi:10.1371/journal.pone.0052895.t004
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(Figure 1) As peripheral constriction with large blind spots is
associated with papilloedema-related optic nerve dysfunction,
HVF supports raised intracranial pressure being an important
cause of optic nerve dysfunction in cryptococcal induced visual
loss. The central field defects found suggest intrinsic optic nerve
disease or secondary macular dysfunction from severe papilloede-
ma; however an inability to test patients with profound visual loss
suggests that the central field defect was probably underestimated
in this patient cohort.
HVF is also strongly correlated with VEP latency prolongation
(p = 0.001 right eyes and p=0.0049 for left eyes) (Table 4).
Subclinical HVF abnormalities were not as frequent as VEP
latency abnormalities and are therefore less sensitive in detecting
optic nerve dysfunction in patients with normal visual acuity in
CM. No significant correlations were noted between HVF and
CSF pressure, optic disc swelling, CD4 counts or VEP amplitude.
The VEP P100 wave is easily recognized on VEP testing and
reproducible. Testing of encephalopathic patients was challenging
in our cohort of patients with CM. In patients who could be tested,
VEP P100 latency was the predominant abnormality and most
strongly correlated with decreased visual acuity and optic disc
swelling. Furthermore, an appreciable number of patients with
normal visual acuity demonstrated P100 latency prolongation
suggesting subclinical disease and perhaps a cohort that require
close monitoring and aggressive management of raised intracranial
pressure to prevent visual loss. The contribution to the P100
latency prolongation made by HIV infection alone needs further
investigation. HVF defects were mostly consistent with raised
intracranial pressure, even though patients with profound visual
loss were unable to be tested.
Prolongation of the P100 latency in early CM lends some
support for focal conduction block and hence the compartment
syndrome from raised intracranial pressure as a cause for visual
loss in these patients. Papilloedema alone which occurs less
frequently than visual loss does not account for most cases of visual
loss, neither does optic neuritis which is uncommon in the pauci-
inflammatory state of CM in HIV infected patients [12]. The
neurapraxia caused by the compression at the optic canal or
orbital segment of the nerve is potentially reversible by lowering of
intracranial pressure rather than immunosuppressant therapy as is
used for idiopathic optic neuritis [8,23].
While this study does demonstrate appreciable P100 latency
prolongation even in asymptomatic CM patients, the long term
implication of this result can only be answered by longitudinal
studies. VEP as a tool to predict visual loss in CM is conceivable
and worth further investigation. Furthermore, VEP and HVF
provide clinical and subclinical evidence for raised intracranial
pressure causing a possible compartment syndrome and optic
nerve dysfunction. So can CSF pressure lowering measures in
addition to offering an improved overall prognosis prevent
blindness in CM by prevention of the optic nerve compartment
syndrome rather than merely preventing papilloedema?
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